vs
Side-by-side financial comparison of FTAI Infrastructure Inc. (FIP) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $143.5M, roughly 2.0× FTAI Infrastructure Inc.). Guardant Health, Inc. runs the higher net margin — -45.7% vs -68.1%, a 22.4% gap on every dollar of revenue. On growth, FTAI Infrastructure Inc. posted the faster year-over-year revenue change (77.7% vs 39.4%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-68.6M). Over the past eight quarters, FTAI Infrastructure Inc.'s revenue compounded faster (31.9% CAGR vs 29.2%).
FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FIP vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.5M | $281.3M |
| Net Profit | $-97.7M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -45.7% | -43.0% |
| Net Margin | -68.1% | -45.7% |
| Revenue YoY | 77.7% | 39.4% |
| Net Profit YoY | 21.6% | -15.8% |
| EPS (diluted) | $-1.04 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $143.5M | $281.3M | ||
| Q3 25 | $140.6M | $265.2M | ||
| Q2 25 | $122.3M | $232.1M | ||
| Q1 25 | $96.2M | $203.5M | ||
| Q4 24 | $80.8M | $201.8M | ||
| Q3 24 | $83.3M | $191.5M | ||
| Q2 24 | $84.9M | $177.2M | ||
| Q1 24 | $82.5M | $168.5M |
| Q4 25 | $-97.7M | $-128.5M | ||
| Q3 25 | $-104.5M | $-92.7M | ||
| Q2 25 | $-70.0M | $-99.9M | ||
| Q1 25 | $120.2M | $-95.2M | ||
| Q4 24 | $-124.7M | $-111.0M | ||
| Q3 24 | $-43.0M | $-107.8M | ||
| Q2 24 | $-48.1M | $-102.6M | ||
| Q1 24 | $-50.3M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -45.7% | -43.0% | ||
| Q3 25 | -70.8% | -37.3% | ||
| Q2 25 | -56.4% | -45.9% | ||
| Q1 25 | 81.8% | -54.6% | ||
| Q4 24 | -152.7% | -62.4% | ||
| Q3 24 | -51.7% | -61.3% | ||
| Q2 24 | -56.4% | -56.8% | ||
| Q1 24 | -58.8% | -59.2% |
| Q4 25 | -68.1% | -45.7% | ||
| Q3 25 | -74.4% | -35.0% | ||
| Q2 25 | -57.2% | -43.0% | ||
| Q1 25 | 125.0% | -46.8% | ||
| Q4 24 | -154.4% | -55.0% | ||
| Q3 24 | -51.6% | -56.3% | ||
| Q2 24 | -56.7% | -57.9% | ||
| Q1 24 | -60.9% | -68.2% |
| Q4 25 | $-1.04 | $-1.01 | ||
| Q3 25 | $-1.38 | $-0.74 | ||
| Q2 25 | $-0.73 | $-0.80 | ||
| Q1 25 | $0.89 | $-0.77 | ||
| Q4 24 | $-1.21 | $-0.90 | ||
| Q3 24 | $-0.45 | $-0.88 | ||
| Q2 24 | $-0.52 | $-0.84 | ||
| Q1 24 | $-0.54 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.4M | $378.2M |
| Total DebtLower is stronger | $3.8B | $1.5B |
| Stockholders' EquityBook value | $21.3M | $-99.3M |
| Total Assets | $5.7B | $2.0B |
| Debt / EquityLower = less leverage | 176.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.4M | $378.2M | ||
| Q3 25 | $34.7M | $580.0M | ||
| Q2 25 | $33.6M | $629.1M | ||
| Q1 25 | $26.3M | $698.6M | ||
| Q4 24 | $27.8M | $525.5M | ||
| Q3 24 | $20.3M | $585.0M | ||
| Q2 24 | $33.1M | $933.7M | ||
| Q1 24 | $23.0M | $1.0B |
| Q4 25 | $3.8B | $1.5B | ||
| Q3 25 | $3.7B | $1.1B | ||
| Q2 25 | $3.1B | $1.1B | ||
| Q1 25 | $2.8B | $1.1B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $21.3M | $-99.3M | ||
| Q3 25 | $181.1M | $-354.5M | ||
| Q2 25 | $375.5M | $-305.5M | ||
| Q1 25 | $476.2M | $-250.8M | ||
| Q4 24 | $202.7M | $-139.6M | ||
| Q3 24 | $370.8M | $-60.1M | ||
| Q2 24 | $394.8M | $-1.6M | ||
| Q1 24 | $402.5M | $68.3M |
| Q4 25 | $5.7B | $2.0B | ||
| Q3 25 | $5.5B | $1.3B | ||
| Q2 25 | $4.4B | $1.3B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $2.4B | $1.5B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B | ||
| Q1 24 | $2.3B | $1.7B |
| Q4 25 | 176.99× | — | ||
| Q3 25 | 20.59× | — | ||
| Q2 25 | 8.21× | — | ||
| Q1 25 | 5.79× | — | ||
| Q4 24 | 7.84× | — | ||
| Q3 24 | 4.14× | — | ||
| Q2 24 | 3.94× | — | ||
| Q1 24 | 3.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.8M | $-26.4M |
| Free Cash FlowOCF − Capex | $-68.6M | $-54.2M |
| FCF MarginFCF / Revenue | -47.8% | -19.3% |
| Capex IntensityCapex / Revenue | 45.9% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-398.5M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.8M | $-26.4M | ||
| Q3 25 | $-24.4M | $-35.4M | ||
| Q2 25 | $-5.2M | $-60.3M | ||
| Q1 25 | $-85.7M | $-62.7M | ||
| Q4 24 | $-8.1M | $-64.5M | ||
| Q3 24 | $14.2M | $-51.1M | ||
| Q2 24 | $-17.6M | $-94.0M | ||
| Q1 24 | $-3.9M | $-30.3M |
| Q4 25 | $-68.6M | $-54.2M | ||
| Q3 25 | $-90.7M | $-45.8M | ||
| Q2 25 | $-87.5M | $-65.9M | ||
| Q1 25 | $-151.7M | $-67.1M | ||
| Q4 24 | $-34.3M | $-83.4M | ||
| Q3 24 | $-11.7M | $-55.3M | ||
| Q2 24 | $-32.1M | $-99.1M | ||
| Q1 24 | $-16.7M | $-37.2M |
| Q4 25 | -47.8% | -19.3% | ||
| Q3 25 | -64.5% | -17.3% | ||
| Q2 25 | -71.6% | -28.4% | ||
| Q1 25 | -157.7% | -33.0% | ||
| Q4 24 | -42.4% | -41.3% | ||
| Q3 24 | -14.0% | -28.9% | ||
| Q2 24 | -37.9% | -55.9% | ||
| Q1 24 | -20.3% | -22.1% |
| Q4 25 | 45.9% | 9.9% | ||
| Q3 25 | 47.2% | 3.9% | ||
| Q2 25 | 67.3% | 2.4% | ||
| Q1 25 | 68.6% | 2.2% | ||
| Q4 24 | 32.5% | 9.4% | ||
| Q3 24 | 31.1% | 2.2% | ||
| Q2 24 | 17.2% | 2.9% | ||
| Q1 24 | 15.6% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIP
| Power Revenues | $45.9M | 32% |
| Rail Revenue | $44.6M | 31% |
| Service Other | $22.8M | 16% |
| Gas Revenues | $15.3M | 11% |
| Roadside Services Revenues | $11.5M | 8% |
| Rapauno | $1.2M | 1% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
